Dutch biotech Laigo Bio bags €17m in oversubscribed seed round

The oversubscribed round, co-led by Biovance Capital and Kurma Partners, adds €5.5m to the initial €11.5m raised in December 2025. Laigo will accelerate its oncology and immunology pipeline using the proprietary SureTAC™ platform. SureTACs are bispecific antibodies that induce degradation by bringing the cell surface target protein into close proximity with a surface E3 ligase enzyme, resulting in highly selective and deep inhibition of disease pathways in affected tissues. “Laigo Bio has shown that its SureTACs degradation technology results in remarkable in vivo and in vitro efficacy, with a high degree of selectivity and improved toxicity and safety,” explained Dr. João Incio, General Partner at Biovance Capital, who joins the company’s Board of Directors.

“The second close of our seed financing round further validates the potential of our SureTACs platform and its ability to identify first-in-class dual targeted therapies to re-define the treatment of cancer and autoimmune diseases,” said Dr. Matthew Baker, Chief Executive Officer of Laigo Bio. Investors include Curie Capital, Angelini Ventures, Eurazeo, Oncode Bridge Fund and Cancer Research Horizons. Laigo plans internal oncology development through preclinical completion before pharma partnerships for clinical entry.

According to Laigo, early data suggest SureTACs could outperform blocking antibodies through deeper pathway inhibition – though clinical proof remains the key milestone ahead.

Laigo’s financing comes amid a flurry of activities in a busy membrane protein degradation field, following recent funding for Ternary Therapeutics and Origami’s deal with Ipsen.